ArGEN-X receives €1.3 million grant for antibody work

Monday 19 December 2011

ArGEN-X BV of the Netherlands has been awarded €1.3 million from a regional Belgian agency to support development of its preclinical antibody portfolio. This follows funding of €27.5 million from a recent Series B venture capital round.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands